ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

Research output: Contribution to journalReview article

176 Scopus citations

Abstract

It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are "addicted" to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide dramatic clinical benefit with little toxicity in patients having such advanced NSCLC, and a mechanism of clinical resistance to crizotinib is identified. Such therapy "targeted" at oncogenic proteins provides "personalized" medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets.

Original languageEnglish (US)
Pages (from-to)548-551
Number of pages4
JournalCancer Cell
Volume18
Issue number6
DOIs
StatePublished - Dec 14 2010

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time'. Together they form a unique fingerprint.

  • Cite this